Arcticzymes Technologies ASA
OSE:AZT

Watchlist Manager
Arcticzymes Technologies ASA Logo
Arcticzymes Technologies ASA
OSE:AZT
Watchlist
Price: 13.16 NOK -2.52%
Market Cap: 684.8m NOK
Have any thoughts about
Arcticzymes Technologies ASA?
Write Note

Net Margin
Arcticzymes Technologies ASA

6.5%
Current
25%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
6.5%
=
Net Income
7m
/
Revenue
108.2m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
NO
Arcticzymes Technologies ASA
OSE:AZT
689.5m NOK
6%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
9%
US
Amgen Inc
NASDAQ:AMGN
150.5B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.9B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
35B EUR
-14%
Country NO
Market Cap 689.5m NOK
Net Margin
6%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 320.1B USD
Net Margin
9%
Country US
Market Cap 150.5B USD
Net Margin
13%
Country US
Market Cap 120.4B USD
Net Margin
-5%
Country US
Market Cap 113.8B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 82.9B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 35B EUR
Net Margin
-14%
No Stocks Found

Arcticzymes Technologies ASA
Glance View

Market Cap
672.1m NOK
Industry
Biotechnology

ArcticZymes Technologies ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. The company is headquartered in Tromso, Troms. The company went IPO on 2005-11-04. The firm focuses on new solutions within molecular research, in vitro diagnostics and therapeutics. Arcticzymes Technologies ASA invests in BetaGlucans, which develops immunomodulating beta-glucan products, serving several different market segments including wound care, animal and consumer health and adjuvants.

AZT Intrinsic Value
21.99 NOK
Undervaluation 40%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
6.5%
=
Net Income
7m
/
Revenue
108.2m
What is the Net Margin of Arcticzymes Technologies ASA?

Based on Arcticzymes Technologies ASA's most recent financial statements, the company has Net Margin of 6.5%.